Journal of Epidemiology and Global Health

Volume 11, Issue 1, March 2021, Pages 15 - 19

Pride and Prejudice during the COVID-19 Pandemic: The Misfortune of Inappropriate Clinical Trial Design

Authors
Shahrukh K. Hashmi1, 2, *, , Edward De Vol3, Fazal Hussain4,
1Clinical Trials Unit, King Faisal Specialist Hospital & Research Centre, Riyadh, KSA
2Division of Hematology, Dept. of Internal Medicine, Mayo Clinic, Rochester, MN, USA
3Dept. of Biostatistics & Epidemiology, King Faisal Specialist Hospital & Research Centre, Riyadh, KSA
4College of Medicine, Alfaisal University, Riyadh, KSA

FH and SKH contributed equally to this work.

*Corresponding author. Email: hashmi.shahrukh@mayo.edu
Corresponding Author
Shahrukh K. Hashmi
Received 17 May 2020, Accepted 12 June 2020, Available Online 7 August 2020.
DOI
10.2991/jegh.k.200729.001How to use a DOI?
Keywords
Clinical trials; single-arm; COVID-19; multi-center; primary endpoint
Abstract

Coronavirus Disease 2019 (COVID-19) is a rapidly evolving global pandemic for which more than a thousand clinical trials have been registered to secure therapeutic effectiveness, expeditiously. Most of these are single-center non-randomized studies rather than multi-center, randomized controlled trials. Single-arm trials have several limitations and may be conducted when spontaneous improvement is not anticipated, small placebo effect exists, and randomization to a placebo is not ethical. In an emergency where saving lives takes precedence, it is ethical to conduct trials with any scientifically proven design, however, safety must not be compromised. A phase II or III trial can be conducted directly in a pandemic with appropriate checkpoints and stopping rules. COVID-19 has two management paradigms- antivirals, or treatment of its complications. Simultaneous assessment of two different treatments can be done using 2 × 2 factorial schema. World Health Organization’s SOLIDARITY trial is a classic example of the global research protocol which can evaluate the preferred treatment to combat COVID-19 pandemic. Short of that, a trial design must incorporate the practicality of the intervention used, and an appropriate primary endpoint which should ideally be a clinical outcome. Collaboration between institutions is needed more than ever to successfully execute and accrue in randomized trials.

Copyright
© 2020 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

Journal
Journal of Epidemiology and Global Health
Volume-Issue
11 - 1
Pages
15 - 19
Publication Date
2020/08/07
ISSN (Online)
2210-6014
ISSN (Print)
2210-6006
DOI
10.2991/jegh.k.200729.001How to use a DOI?
Copyright
© 2020 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - JOUR
AU  - Shahrukh K. Hashmi
AU  - Edward De Vol
AU  - Fazal Hussain
PY  - 2020
DA  - 2020/08/07
TI  - Pride and Prejudice during the COVID-19 Pandemic: The Misfortune of Inappropriate Clinical Trial Design
JO  - Journal of Epidemiology and Global Health
SP  - 15
EP  - 19
VL  - 11
IS  - 1
SN  - 2210-6014
UR  - https://doi.org/10.2991/jegh.k.200729.001
DO  - 10.2991/jegh.k.200729.001
ID  - Hashmi2020
ER  -